<DOC>
	<DOC>NCT00700063</DOC>
	<brief_summary>This Phase IIb study is designed to assess the safety and efficacy of 0.005%, 0.01% and 0.015% PEP005 Topical Gel when applied to an area of skin, containing 4-8 AK lesions on the face or scalp.</brief_summary>
	<brief_title>A Multicenter Study to Evaluate the Safety and Efficacy of PEP005 Topical Gel When Used to Treat Actinic Keratoses on the Head (Face or Scalp)</brief_title>
	<detailed_description />
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis, Actinic</mesh_term>
	<criteria>Must be male or female Female patients must be of Nonchildbearing potential; Childbearing potential, provided negative pregnancy test and using effective contraception 4 to 8 AK lesions on the face or scalp Cosmetic or therapeutic procedures within 2 weeks and within 2 cm of the selected treatment area. Treatment with immunomodulators, or interferon/ interferon inducers or systemic medications that suppress the immune system: within 4 weeks. Treatment with 5FU, imiquimod, diclofenac, or photodynamic therapy: within 8 weeks and 2 cm of treatment area</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Peplin</keyword>
	<keyword>Actinic keratosis</keyword>
	<keyword>PEP005</keyword>
</DOC>